Chiesi Farmaceutici yesterday announced it has acquired the Laevolac brand from Roche and the Marco Antonetto company with its product portfolio. The move will strengthen Chiesi’s position in the OTC business and will grant it access to the gastrointestinal treatments and nutraceuticals businesses. The company has not disclosed the financial details of the transaction yet.
(Source: Chiesi)